Acuitive Technologies has introduced its new Citrelock ACL Tendon Fixation Device for sports medicine.
Rutgers-New Jersey Medical School orthopaedics professor Robin Gehrmann completed the implantation of the first ACL device, saying: “By leveraging Citregen’s unique material properties, the Citrelock Tendon Fixation Device introduces design features to ease insertion and secure fixation without damaging the tendon during placement.”
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new device offers surgeons a differentiated design through a tendon-friendly spiral thread, which features a next-generation resorbable technology called Citregen.
Citregen has unique molecular and mechanical properties for orthopaedic surgical applications.
The device provides biomimetic material composition to match the native bone inorganic content, as well as a compressive strength that is similar to cortical bone and a modulus-like trabecular bone.
It also offers elastomeric properties for enhanced pull-out strength and a controlled resorption rate to address chronic inflammation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAcuitive product development vice-president Rui Ferreira said: “The Citrelock ACL Tendon Fixation Device helps fill that clinical need with its innovative material technology and unique design.
“Citrelock ACL System is an exciting addition to Acuitive’s portfolio and is the first in a series of new products we will be launching with a focus on the Sports Medicine market.”
Acuitive is involved in the development of advanced biomaterials and orthopaedic devices to support the natural healing process of musculoskeletal tissues.
